JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma
SHANGHAI, July 4, 2022 /PRNewswire/ — JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing